Related Experiment Video

Updated: Mar 18, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

RNAi-combined nano-chemotherapeutics to tackle resistant tumors

Rakesh Kumar Tekade1, Muktika Tekade2, Prashant Kesharwani3

  • 1National Institute of Pharmaceutical Education and Research (NIPER), Sarkhej - Gandhinagar Highway, Thaltej, Ahmedabad-380054, Gujarat, India.

Drug Discovery Today
|July 7, 2016
PubMed

Insights

Nanotechnology combined with chemotherapy and small interfering RNAs (siRNAs) offers a promising strategy to overcome drug-resistant tumors. This approach protects siRNAs and enhances anticancer therapy effectiveness.

Area of Science:

  • Oncology
  • Nanomedicine
  • Molecular Biology

Background:

  • Drug-resistant tumors pose a significant challenge in cancer therapy.
  • Combination chemotherapy and small interfering RNAs (siRNAs) are emerging strategies.
  • Nanotechnology offers potential solutions for drug delivery and stability.

Purpose of the Study:

  • To review nanotechnology-based approaches for delivering siRNAs and chemotherapeutic drugs.
  • To discuss the potential of combining nanotechnology, siRNAs, and chemotherapy for resistant tumors.
  • To highlight considerations for developing nanotechnology-assisted siRNA-drug cancer therapies.

Main Methods:

  • Review of current scientific literature on nanotechnology-assisted drug delivery systems.
  • Analysis of studies investigating siRNA combinations with chemotherapeutic agents.
  • Discussion of siRNA targets including VEGF, XLAP, PGP, MRP-1, BCL-2, and cMyc.

Main Results:

  • siRNAs demonstrate potential in knocking out drug resistance genes and restoring tumor sensitivity.
  • Nanotechnology can protect siRNAs from degradation and reduce off-target effects.
  • Combined approaches show promise for treating resistant cancers.

Conclusions:

  • Nanotechnology-enhanced combination therapy with siRNAs and chemotherapeutic drugs is a promising avenue for resistant tumors.
  • Careful consideration of formulation and delivery is crucial for successful clinical translation.
  • This strategy holds potential to improve patient outcomes in oncology.

More Related Videos

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

1.4K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
723
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K